Interview with Peter Martin, COO, Norgine
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Address: Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom ,United Kingdom
Tel: +44 (0) 1344 424 600
Web: http://www.boehringer-ingelheim.co.uk/
Boehringer Ingelheim is a family owned company whose distinctly independent structure means that we are not constrained by the short-term needs of individual shareholders and can focus on the future with long-term strategies of vision and leadership. Boehringer Ingelheim was founded in 1885 by Albert Boehringer and remains a familyowned company. Today we are the fastest growing company amongst the world’s 15 leading pharmaceutical companies.
Annual sales are €12.7 billion worldwide (2009) and 21% of the net sales from its Prescription Medicine business is invested into research and development. The company now employ more than 41,500 people and is committed to remaining family-owned. Albert’s great grandson, Christian Boehringer, is the Chair of the Shareholders’ Committee which manages 142 affiliated companies in 50 countries around the globe. Our headquarters remain in Ingelheim, near Frankfurt in Germany.
Boehringer Ingelheim’s vision, ‘Value through Innovation’, mirrors the founder’s own belief in the importance of innovative thinking and that, as well as being financially profitable, products should be pioneering and of genuine benefit to patients. This independent status frees the company from stock market expectations, and allows for long-term strategies, rather than short-term priorities.
In the United Kingdom, Boehringer Ingelheim was established in 1962 and is one of the fastest growing pharmaceutical companies in the UK, with total sales of £388 million in 2009 (independent audit). The business focuses on clinical research, data management, sales and marketing.
Boehringer Ingelheim is involved in three key healthcare areas: Prescription Medicines, Over-The-Counter (OTC) products and Animal Health. In each sector, the company has world-class medicines to treat patients.
The company has a reputation for providing effective products for the treatment of chronic obstructive pulmonary disease (COPD), heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson’s disease, arthritis and pain relief in cancer.
These products are supported by a wide range of services, designed to help the medical profession deliver the best possible healthcare to patients.
This underlines Boehringer Ingelheim’s commitment to improving health and quality of life in the UK.
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
See our Cookie Privacy Policy Here